<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00059787</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2013-00026</org_study_id>
    <secondary_id>NYU 02-30</secondary_id>
    <secondary_id>N01CM62204</secondary_id>
    <nct_id>NCT00059787</nct_id>
  </id_info>
  <brief_title>Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma</brief_title>
  <official_title>Phase II Study of Erlotinib Plus Carboplatin and Paclitaxel in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial is studying the side effects of giving erlotinib together with
      carboplatin and paclitaxel and to see how well it works in treating patients with stage III
      or stage IV ovarian, fallopian tube, or primary peritoneal cancer. Biological therapies such
      as erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor.
      Drugs used in chemotherapy such as carboplatin and paclitaxel use different ways to stop
      tumor cells from dividing so they stop growing or die.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To establish whether the addition of OSI-774 (Tarceva) to the combination of paclitaxel
      and carboplatin encourages pathologic complete response (pCR) rates in patients with Stage
      III optimally cytoreduced (stratum 1) and Stage III suboptimally cytoreduced or Stage IV
      (stratum 2) ovarian, primary peritoneal or fallopian tube carcinomas when used as front line
      therapy.

      II. To determine the degree and type of toxicity associated with this combined regimen.

      SECONDARY OBJECTIVES:

      I. To establish baseline epidermal growth factor receptor (EGFR), truncated EGFR (EGFRvIII),
      phosphorylated EGFR (pEGFR) and related signal transduction pathway protein expression levels
      (such as the mitogen activated protein kinase p-ERK, AKT phosphorylation and Her2/neu) in
      tumor samples obtained pretreatment, and to correlate these with achieving pCR.

      II. To describe changes in EGFR, EGFRvIII, pEGFR expression levels and other related signal
      transduction pathway expression occurring during treatment with OSI-774 in combination with
      chemotherapy.

      III. To determine the effect of the addition of OSI-774 (Tarceva) to the combination of
      paclitaxel and carboplatin on progression-free interval in patients with Stage III optimally
      cytoreduced (stratum 1) and Stage III suboptimally cytoreduced or Stage IV (stratum 2)
      ovarian or primary peritoneal carcinomas when used as front line therapy.

      IV. To determine the tolerability of twelve months of maintenance treatment with OSI-774 for
      patients achieving pCR, and to measure the progression-free interval for this population.

      V. To document cutaneous effects of OSI 774 prospectively, and to correlate the degree of
      skin rash with clinical and translational endpoints.

      OUTLINE: This is a non-randomized study. Patients are stratified according to disease stage
      (stage III with optimal residual disease vs stage III with suboptimal residual disease or
      stage IV).

      Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1.
      Patients also receive oral erlotinib daily. Treatment repeats every 21 days for up to 6
      courses in the absence of disease progression or unacceptable toxicity. Patients who achieve
      a pathologic complete response, those initially suboptimally debulked with a response, and
      patients who elect not to undergo surgical reassessment but who achieve a complete clinical
      response receive maintenance erlotinib for an additional 12 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2003</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathologic Complete Response Rates</measure>
    <time_frame>Up to 7 years</time_frame>
    <description>Pathologic complete response was defined as having no pathologic or cytologic evidence of disease following surgical reassessment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Percentage of Participants Experiencing Toxicty (Grade 2 and Grade 3/4) Associated With the Combined Regimen</measure>
    <time_frame>For the duration of the study up to 7 years</time_frame>
    <description>Adverse event assessment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To Measure EGFR Gene Amplification in Tumor Specimens</measure>
    <time_frame>The duration of the study for up to 7 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Determine Progession Free Survival With the Addition of OSI-774 (Tarceva) to the Combination of Paclitaxel and Carboplatin</measure>
    <time_frame>The duration of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Determine the Tolerability of Twelve Months of Maintenance Treatment</measure>
    <time_frame>Twelve months of maintenance</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Brenner Tumor</condition>
  <condition>Fallopian Tube Cancer</condition>
  <condition>Ovarian Clear Cell Cystadenocarcinoma</condition>
  <condition>Ovarian Endometrioid Adenocarcinoma</condition>
  <condition>Ovarian Mucinous Cystadenocarcinoma</condition>
  <condition>Ovarian Serous Cystadenocarcinoma</condition>
  <condition>Ovarian Undifferentiated Adenocarcinoma</condition>
  <condition>Stage III Ovarian Epithelial Cancer</condition>
  <condition>Stage IV Ovarian Epithelial Cancer</condition>
  <arm_group>
    <arm_group_label>Paclitaxel, carboplatin, erlotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carboplatin and paclitaxel IV every 21 days x 6 cycles plus oral erlotinib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Paclitaxel, carboplatin, erlotinib</arm_group_label>
    <other_name>Anzatax</other_name>
    <other_name>Asotax</other_name>
    <other_name>TAX</other_name>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Paclitaxel, carboplatin, erlotinib</arm_group_label>
    <other_name>Carboplat</other_name>
    <other_name>CBDCA</other_name>
    <other_name>JM-8</other_name>
    <other_name>Paraplat</other_name>
    <other_name>Paraplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Paclitaxel, carboplatin, erlotinib</arm_group_label>
    <other_name>CP-358,774</other_name>
    <other_name>OSI-774</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with a histologic diagnosis of primary peritoneal carcinoma, fallopian tube
             epithelial ovarian carcinoma, Stage III with either greater than 1 cm (suboptimal)
             residual disease following initial surgery, or Stage IV; all patients must either have
             had appropriate surgery for ovarian, fallopian tube or peritoneal carcinoma with
             appropriate tissue available for histologic evaluation to confirm diagnosis and stage
             or must be unresectable at time of diagnosis (to be determined by gynecological
             oncologist); cytology alone is not adequate

          -  Patients with the following histologic epithelial cell types are eligible: Serous
             adenocarcinoma, endometrioid adenocarcinoma, mucinous adenocarcinoma, undifferentiated
             carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, transitional cell
             carcinoma, malignant Brenner's Tumor, or adenocarcinoma not otherwise specified (NOS)

          -  Patients must begin chemotherapy on this study no more than twelve weeks
             postoperatively

          -  Patients must not have received chemotherapy within five years prior to enrollment

          -  ECOG performance status =&lt; 2 (Karnofsky &gt;= 60%)

          -  Absolute neutrophil count &gt;= 1,500/uL

          -  Platelets &gt;= 100,000/uL

          -  Total bilirubin =&lt; 1.5 x institutional upper limit of normal

          -  AST(SGOT)/ALT(SGPT) =&lt; 2.5 x institutional upper limit of normal

          -  Creatinine =&lt; 1.5 x institutional upper limit of normal OR creatinine clearance &gt;= 60
             mL/min/1.73 m^2 for patients with creatinine levels above institutional normal

          -  Neuropathy (sensory and motor) =&lt; CTC grade 1

          -  No medical contraindications to planned regimen

          -  Ability to understand and the willingness to sign a written informed consent document

        Exclusion Criteria:

          -  Patients who have had courses of chemotherapy within the five years prior to entering
             the study

          -  Patients may not be receiving any other investigational agents

          -  Patients with known brain metastases should be excluded from this clinical trial
             because of their poor prognosis and because they often develop progressive neurologic
             dysfunction that would confound the evaluation of neurologic and other adverse events

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition OSI-774 or other agents used in the study

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements

          -  Pregnant women are excluded from this study because OSI-774 has the potential for
             teratogenic or abortifacient effects; because there is an unknown but potential risk
             for adverse events in nursing infants secondary to treatment of the mother with
             OSI-774, breastfeeding should be discontinued if the mother is treated with OSI-774;
             these potential risks may also apply to other agents used in this study

          -  Because patients with immune deficiency are at increased risk of lethal infections
             when treated with marrow-suppressive therapy, HIV-positive patients receiving
             combination anti-retroviral therapy are excluded from the study because of possible
             pharmacokinetic interactions with OSI-774 or other agents administered during the
             study; appropriate studies will be undertaken in patients receiving combination
             anti-retroviral therapy when indicated
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephanie Blank</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montefiore Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467-2490</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Blank SV, Christos P, Curtin JP, Goldman N, Runowicz CD, Sparano JA, Liebes L, Chen HX, Muggia FM. Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: a phase II study based on surgical reassessment. Gynecol Oncol. 2010 Dec;119(3):451-6. doi: 10.1016/j.ygyno.2010.08.008. Epub 2010 Sep 15.</citation>
    <PMID>20837357</PMID>
  </results_reference>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 6, 2003</study_first_submitted>
  <study_first_submitted_qc>May 6, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2003</study_first_posted>
  <results_first_submitted>April 29, 2015</results_first_submitted>
  <results_first_submitted_qc>October 29, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 1, 2015</results_first_posted>
  <last_update_submitted>October 29, 2015</last_update_submitted>
  <last_update_submitted_qc>October 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Neoplasms, Glandular and Epithelial</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
    <mesh_term>Cystadenocarcinoma</mesh_term>
    <mesh_term>Carcinoma, Endometrioid</mesh_term>
    <mesh_term>Cystadenocarcinoma, Serous</mesh_term>
    <mesh_term>Cystadenocarcinoma, Mucinous</mesh_term>
    <mesh_term>Brenner Tumor</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 56 patients were enrolled between June 2003 and December 2006.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment (Paclitaxel, Carboplatin, Erlotinib Hydrochloride)</title>
          <description>Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Patients also receive oral erlotinib daily. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve a pathologic complete response, those initially suboptimally debulked with a response, and patients who elect not to undergo surgical reassessment but who achieve a complete clinical response receive maintenance erlotinib for an additional 12 months.
paclitaxel: Given IV
carboplatin: Given IV
erlotinib hydrochloride: Given PO
laboratory biomarker analysis: Correlative studies</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>disease progression</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>ineligible</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment (Paclitaxel, Carboplatin, Erlotinib Hydrochloride)</title>
          <description>Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Patients also receive oral erlotinib daily. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve a pathologic complete response, those initially suboptimally debulked with a response, and patients who elect not to undergo surgical reassessment but who achieve a complete clinical response receive maintenance erlotinib for an additional 12 months.
paclitaxel: Given IV
carboplatin: Given IV
erlotinib hydrochloride: Given PO
laboratory biomarker analysis: Correlative studies</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="56"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.5" lower_limit="22" upper_limit="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pathologic Complete Response Rates</title>
        <description>Pathologic complete response was defined as having no pathologic or cytologic evidence of disease following surgical reassessment.</description>
        <time_frame>Up to 7 years</time_frame>
        <population>Patients who had optimally debulking surgery</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Paclitaxel, Carboplatin, Erlotinib Hydrochloride)</title>
            <description>Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Patients also receive oral erlotinib daily. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve a pathologic complete response, those initially suboptimally debulked with a response, and patients who elect not to undergo surgical reassessment but who achieve a complete clinical response receive maintenance erlotinib for an additional 12 months.
paclitaxel: Given IV
carboplatin: Given IV
erlotinib hydrochloride: Given PO
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Pathologic Complete Response Rates</title>
          <description>Pathologic complete response was defined as having no pathologic or cytologic evidence of disease following surgical reassessment.</description>
          <population>Patients who had optimally debulking surgery</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Percentage of Participants Experiencing Toxicty (Grade 2 and Grade 3/4) Associated With the Combined Regimen</title>
        <description>Adverse event assessment</description>
        <time_frame>For the duration of the study up to 7 years</time_frame>
        <population>Patients enrolled on all stratums included</population>
        <group_list>
          <group group_id="O1">
            <title>Paclitaxel, Carboplatin, Erlotinib</title>
            <description>Carboplatin and paclitaxel IV every 21 days x 6 cycles plus oral erlotinib
paclitaxel: Given IV
carboplatin: Given IV
erlotinib: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Participants Experiencing Toxicty (Grade 2 and Grade 3/4) Associated With the Combined Regimen</title>
          <description>Adverse event assessment</description>
          <population>Patients enrolled on all stratums included</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 3-4 neutropenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3-4 skin rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3-4 thrombocytopenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3-4 infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3-4 fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2 skin rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2 diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Measure EGFR Gene Amplification in Tumor Specimens</title>
        <time_frame>The duration of the study for up to 7 years</time_frame>
        <population>Tumor specimens were evaluated for EGFR gene amplification in 20 patients</population>
        <group_list>
          <group group_id="O1">
            <title>Paclitaxel, Carboplatin, Erlotinib</title>
            <description>Carboplatin and paclitaxel IV every 21 days x 6 cycles plus oral erlotinib
paclitaxel: Given IV
carboplatin: Given IV
erlotinib: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>To Measure EGFR Gene Amplification in Tumor Specimens</title>
          <population>Tumor specimens were evaluated for EGFR gene amplification in 20 patients</population>
          <units>number of tumor specimens</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No amplification</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low-level amplification</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>moderate high amplification</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Determine Progession Free Survival With the Addition of OSI-774 (Tarceva) to the Combination of Paclitaxel and Carboplatin</title>
        <time_frame>The duration of the study</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Paclitaxel, Carboplatin, Erlotinib Hydrochloride)</title>
            <description>Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Patients also receive oral erlotinib daily. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve a pathologic complete response, those initially suboptimally debulked with a response, and patients who elect not to undergo surgical reassessment but who achieve a complete clinical response receive maintenance erlotinib for an additional 12 months.
paclitaxel: Given IV
carboplatin: Given IV
erlotinib hydrochloride: Given PO
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>To Determine Progession Free Survival With the Addition of OSI-774 (Tarceva) to the Combination of Paclitaxel and Carboplatin</title>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.3" lower_limit="23.9" upper_limit="51.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Determine the Tolerability of Twelve Months of Maintenance Treatment</title>
        <time_frame>Twelve months of maintenance</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Paclitaxel, Carboplatin, Erlotinib Hydrochloride)</title>
            <description>Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Patients also receive oral erlotinib daily. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve a pathologic complete response, those initially suboptimally debulked with a response, and patients who elect not to undergo surgical reassessment but who achieve a complete clinical response receive maintenance erlotinib for an additional 12 months.
paclitaxel: Given IV
carboplatin: Given IV
erlotinib hydrochloride: Given PO
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>To Determine the Tolerability of Twelve Months of Maintenance Treatment</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No recurrence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Recurrence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Treatment (Paclitaxel, Carboplatin, Erlotinib Hydrochloride)</title>
          <description>Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Patients also receive oral erlotinib daily. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve a pathologic complete response, those initially suboptimally debulked with a response, and patients who elect not to undergo surgical reassessment but who achieve a complete clinical response receive maintenance erlotinib for an additional 12 months.
paclitaxel: Given IV
carboplatin: Given IV
erlotinib hydrochloride: Given PO
laboratory biomarker analysis: Correlative studies</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Alanine transaminase</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Aspartate transaminase</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash: desquamation</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Mucositis: oral</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Pain: abdomen</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash: desquamation</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>NYCC Regulatory Coordinator</name_or_title>
      <organization>Montefiore Medical Center - New York Cancer Consortium</organization>
      <phone>718-379-6862</phone>
      <email>sforde@montefiore.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

